Literature DB >> 3260637

Trimethoprim-sulfamethoxazole desensitization in AIDS.

G Papakonstantinou1, H Füessl, R Hehlmann.   

Abstract

Trimethoprim-sulfamethoxazole (TMS) desensitization was carried out in three patients with AIDS and Pneumocystis carinii pneumonia (PCP) in whom treatment with TMS had to be discontinued after 8 to 12 days due to an allergic reaction. Although the pneumonia was under control we decided for a desensitization to TMS because of the frequent reinfection and the high mortality rate particularly if treatment is incomplete. On the first day the patients took 0.4 mg/2 mg trimethoprim/sulfamethoxazole orally. The dose was increased during 9 successive days to 80 mg/400 mg trimethoprim/sulfamethoxazole. From the 10th to the 16th day 160 mg/800 mg trimethoprim/sulfamethoxazole was given daily and subsequently twice daily which is the recommended dose for prophylaxis of PCP. The desensitization was successful in two patients and a PCP prophylaxis was possible.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260637     DOI: 10.1007/bf01735793

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  20 in total

1.  NHLBI workshop summary. Pulmonary complications of the acquired immunodeficiency syndrome: an update. Report of the second National Heart, Lung and Blood Institute workshop.

Authors:  J F Murray; S M Garay; P C Hopewell; J Mills; G L Snider; D E Stover
Journal:  Am Rev Respir Dis       Date:  1987-02

2.  Trimethoprim-sulfamethoxazole desensitization in the acquired immunodeficiency syndrome.

Authors:  R M Smith; G K Iwamoto; H B Richerson; J P Flaherty
Journal:  Ann Intern Med       Date:  1987-02       Impact factor: 25.391

3.  Sulphasalazine desensitisation.

Authors:  C D Holdsworth
Journal:  Br Med J (Clin Res Ed)       Date:  1981-01-10

4.  Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia.

Authors:  W T Hughes; S Feldman; S C Chaudhary; M J Ossi; F Cox; S K Sanyal
Journal:  J Pediatr       Date:  1978-02       Impact factor: 4.406

5.  Neuroleukin: a lymphokine product of lectin-stimulated T cells.

Authors:  M E Gurney; B R Apatoff; G T Spear; M J Baumel; J P Antel; M B Bania; A T Reder
Journal:  Science       Date:  1986-10-31       Impact factor: 47.728

6.  Molecular cloning and expression of neuroleukin, a neurotrophic factor for spinal and sensory neurons.

Authors:  M E Gurney; S P Heinrich; M R Lee; H S Yin
Journal:  Science       Date:  1986-10-31       Impact factor: 47.728

7.  Autoimmune thrombocytopenic purpura in homosexual men.

Authors:  L Morris; A Distenfeld; E Amorosi; S Karpatkin
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

8.  Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole.

Authors:  W T Hughes; S Feldman; S K Sanyal
Journal:  Can Med Assoc J       Date:  1975-06-14       Impact factor: 8.262

9.  Incidence and mortality of adult respiratory distress syndrome: a prospective analysis from a large metropolitan hospital.

Authors:  W R Baumann; R C Jung; M Koss; C T Boylen; L Navarro; O P Sharma
Journal:  Crit Care Med       Date:  1986-01       Impact factor: 7.598

10.  Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; P C McNabb; T D Makres; S Feldman
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

View more
  1 in total

1.  Therapy of pneumocystis carinii pneumonia after trimethoprim-sulfamethoxazole desensitization.

Authors:  G Papakonstantinou; H Füessl; A Matuschke; R Hehlmann
Journal:  Klin Wochenschr       Date:  1989-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.